Company profile: Codexis
1.1 - Company Overview
Company description
- Provider of enzyme discovery and RNA manufacturing solutions, offering the CodeEvolver platform to discover, develop, and enhance novel enzymes and proteins; ECO Synthesis technology for scaled enzymatic production of RNAi therapeutics; custom enzymes to improve small molecule pharmaceutical manufacturing; RNA ligase screening and optimization; and high-yield RNA manufacturing services.
Products and services
- ECO Synthesis™ Technology: Industrial-scale platform enabling scaled production of RNAi therapeutics through enzymatic synthesis for manufacturing therapeutic RNAi at production scale
- CodeEvolver® Platform: Proprietary platform that discovers, develops, and enhances novel enzymes and proteins for various applications, enabling targeted enzyme and protein optimization for specified uses
- Pharma Manufacturing Enzymes: Custom-engineered enzymes developed to improve manufacturing processes of small molecule pharmaceuticals, supplying tailored enzymes for small-molecule drug manufacturing workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Codexis
Eligo Bioscience
HQ: France
Website
- Description: Provider of CRISPR/Cas and engineered phage capsid-based antimicrobials and microbiome editing technologies to control bacterial ecosystems in humans and animals. Solutions include the GEM platform for in vivo gene editing, SSAM sequence-specific antimicrobials, FAME for therapeutic gene addition, and capabilities for gene removal, modification, and addition to eradicate resistant pathogens and modulate disease mechanisms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eligo Bioscience company profile →
Denovo Biopharma
HQ: United States
Website
- Description: Provider of biomarker-driven personalized drug development, advancing a pipeline of therapeutics: DB107, a cancer-selective immunotherapy combining gene therapy with a prodrug conversion strategy; DB102 (enzastaurin) guided by DGM1 for DLBCL/GBM; psychiatric candidates DB104 (TRD), DB103 (mGlu2/3), DB105 for Alzheimer’s; and oncology agent DB106 (vosaroxin) for AML and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Denovo Biopharma company profile →
Crescendo Bioscience
HQ: United States
Website
- Description: Provider of quantitative, objective diagnostic tools for rheumatologists, delivering clinical insights to manage patients with autoimmune and inflammatory diseases. Provides diagnostic, prognostic, staging, therapy selection, and monitoring facilities to physicians.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crescendo Bioscience company profile →
Instant Labs
HQ: United States
Website
- Description: Provider of a fully-integrated, portable, and affordable real-time polymerase chain reaction (RT-PCR) platform for rapid, accurate pathogen detection, developing and marketing the Hunter Real-Time-PCR system. Focus areas include molecular diagnostic equipment, food safety testing equipment, and food verification testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Instant Labs company profile →
Tute Genomics
HQ: United States
Website
- Description: Provider of a cloud-based clinical genome interpretation platform that rapidly analyzes and annotates personal genomes, enabling researchers and clinicians to utilize human genome data for scientific discovery and individualized treatment, incorporating proprietary machine-learning algorithms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tute Genomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Codexis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Codexis
2.2 - Growth funds investing in similar companies to Codexis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Codexis
4.2 - Public trading comparable groups for Codexis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →